Betahistine, tablets 24 mg 60 pcs

Pharmacotherapeutic group

Histamine drug

ATX code

N07CA01

Pharmacodynamics:

An agonist of H1-histamine receptors of the inner ear vessels and an antagonist of H3-histamine receptors of the vestibular nuclei of the central nervous system (CNS). By relaxing the precapillary sphincters of the vessels of the inner ear, it improves blood circulation in the vascular band of the inner ear.

Dose-dependently reduces the generation of action potentials in the neurons of the lateral and medial vestibular nuclei.

Accelerates recovery of vestibular function after unilateral vestibular neurectomy by accelerating and facilitating central vestibular compensation (due to antagonism with H3-histamine receptors).

It alleviates symptoms in Meniere’s syndrome and vestibular vertigo.

Stable therapeutic effect occurs after 14 days.

Pharmacokinetics:

Absorbed rapidly binding to plasma proteins is less than 5%. Time of reaching maximum concentration in blood plasma (TCmax) – 1 hour.

Metabolized to inactive metabolites: 2-pyridylacetic acid (the main metabolite) and demethylbetahistine. 85-90% is excreted by the kidneys as 2-pyridylacetic acid within 24 hours. Excretion of betahistine and demethylbetahistine by the kidneys is insignificant. The intestine excretes only a small part of betahistine and its metabolites. When the drug is taken with food, the maximum concentration of betahistine is lower than when taken on an empty stomach. However, the total absorption of betahistine is the same in both cases, indicating that eating only slows absorption of betahistine.

Indications

Treatment of Meniere’s syndrome characterized by vertigo (accompanied by nausea and vomiting), decreased hearing and tinnitus.

The symptomatic treatment of vestibular vertigo.

Active ingredient

Betahistine

Composition

Each tablet contains:

Active ingredient: betahistine dihydrochloride – 24.0 mg.

Excipients: lactose monohydrate (milk sugar) – 129.0 mg; microcrystalline cellulose – 70.5 mg; corn starch – 30.0 mg; copovidone – 27.0 mg; sodium carboxymethyl starch – 15.0 mg; colloidal silicon dioxide – 1.5 mg; magnesium stearate – 3.0 mg.

How to take, the dosage

Orally with meals on 1 tablet (24 mg) 2 times a day Treatment is long. The course of treatment is determined individually. Dosage adjustment in elderly persons is not required.

Interaction

The interaction of betahistine with H1-histamine receptor blockers when used concomitantly may theoretically affect the efficacy of one of these agents.

Special Instructions

Therapeutic effect in a number of cases builds up within a few months of the start of treatment.

Influence on the ability to drive:

There is no or negligible effect.

Contraindications

Hypersensitivity to the components of the drug pregnancy lactation period childhood age under 18 years pheochromocytoma lactose intolerance lactase deficiency glucose-galactose malabsorption.

With caution: Gastric or 12 duodenal ulcer (history) bronchial asthma.

Side effects

Digestive system: nausea dyspepsia vomiting abdominal pain abdominal distension.

Allergic reactions: hypersensitivity including anaphylactic reactions.

Skin disorders: angioedema urticaria itching rash.

Nervous system disorders:headache.

Overdose

Symptoms: nausea abdominal pain drowsiness (when taken in doses up to 640 mg); convulsions cardiopulmonary complications (when taken in doses greater than 640 mg or in combination with other drugs).

Treatment: symptomatic.

Similarities

Betaserk, Vestibo, Betahistine, Betahistine NW, Tagista, Vertran